Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Beta-1b and Remdesivir for COVID-19
NCT04647695Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon beta-1b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Clinical improvement at 30 days. Status: unknown.
02
Drugs
interferon beta-1b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04647695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647695.